SARIFA as a new histopathological biomarker is associated with adverse clinicopathological characteristics, tumor-promoting fatty-acid metabolism, and might predict a metastatic pattern in pT3a prostate cancer

Table 2 Univariate Cox regression analysis regarding overall survival in pT3a prostate cancer

	Univariate Cox Regression
Overall Survival	Hazard Ratio (95% CI)	p-value
iPSA	1.031 (1.014–1.048)	< 0.001
Age > 65	1.743 (0.879–3.454)	0.112
Extraprostatic extension (focal vs non-focal)	0.718 (0.293–1.758)	0.469
pN (pN0 vs pN1)	0.768 (0.413–1.430)	0.405
R status (R0 vs R1)	1.003 (0.591–1.704)	0.99
Lymphatic invasion (no vs yes)	1.097 (0.459–2.621)	0.835
Vascular invasion (no vs yes)	1.631 (0.386–6.883)	0.506
Perineural invasion	2.772 (0.380–20.245)	0.315
*Risk group	1.227 (0.765–1.969)	0.395
SARIFA (negative vs positive)	1.290 (0.758–2.196)	0.348

p-values that are statistically significant are highlighted in bold
*iPSA: initial prostate specific antigen values were only available for 211 patients. SARIFA Stroma-AReactive-Invasion-Front-Areas, pT depth of invasion, pN lymph node status, R status residual tumor status; Extraprostatic extension according to Ball et al. [19]; *Simplified risk groups are defined as: Grade Group 1 = 1; Grade Group 2 and 3 = 2; Grade Group 4 and 5 = 3 [20]

ISSN: 1471-2407